The most exciting application for RIA in 2026 is the hunt for "Neuro-Biomarkers" in the early stages of neurodegenerative diseases. As we tackle the global challenge of aging, the ability to detect "Alpha-Synuclein" and "Amyloid-Beta" at concentrations previously thought unmeasurable is becoming a 2026 medical priority. RIA's unique ability to "Sift through the Noise" of complex brain-derived...